Results 61 to 70 of about 13,171 (198)

Tumor Cell‐Expressed Herpesvirus Entry Mediator Regulates Proliferation and Adaptive Immunity in Ovarian Cancer

Immunity, Inflammation and Disease
Background Ovarian cancer (OvCa) is a prevalent gynecological malignancy with an increasing incidence and high mortality rate. Although the role of the herpesvirus entry mediator (HVEM), encoded by the TNFRSF14 gene, is currently considered pivotal in ...
Yun Lu, Yijun Zhang, Wenxuan Li, Haonan Jiang, Jiapo Wang, Xiaoqing Guo   +5 more
doaj   +1 more source

Herpesvirus Entry Mediator as an Immune Checkpoint Target and a Potential Prognostic Biomarker in Myeloid and Lymphoid Leukemia

Biomolecules
Herpesvirus entry mediator (HVEM) is a molecular switch that can modulate immune responses against cancer. The significance of HVEM as an immune checkpoint target and a potential prognostic biomarker in malignancies is still controversial.
Fatemah S. Basingab, Reem A. Alzahrani, Aisha A. Alrofaidi, Ahmed S. Barefah, Rawan M. Hammad, Hadil M. Alahdal, Jehan S. Alrahimi, Kawther A. Zaher, Ali H. Algiraigri, Mai M. El-Daly, Saleh A. Alkarim, Alia M. Aldahlawi   +11 more
doaj   +1 more source

Islamsk emirat i Gaza? Hamas vs. al-Qaida

Babylon, 2016
Siden valget af Hamas i 2006 er der opstået en opposition af al-Qaidainspirerede bevægelser i Gaza. Ideologiske modsætninger har ført til konflikt mellem disse grupper og Hamas. Men hvem truer hvem i denne situation?
Troels Gauslå Engell
doaj   +1 more source

T follicular helper expansion and humoral-mediated rejection are independent of the HVEM/BTLA pathway

[EN] The molecular pathways contributing to humoral-mediated allograft rejection are poorly defined. In this study, we assessed the role of the herpesvirus entry mediator/B- and T-lymphocyte attenuator (HVEM/BTLA) signalling pathway in the context of ...
Bühler, Leo, Río González, María Luisa del, Bravo Moral, Ana María, Rodríguez Barbosa, José Ignacio, Fernández Renedo, Carlos   +4 more
core   +1 more source

HVEM : a promising new target for cancer immunotherapy

, 2023
Ces dernières années, l'essor des immunothérapies a transformé la prise en charge des patients atteints de cancers avancés. Les stratégies actuelles visant PD-1/PD-L1 ou CTLA-4 permettent d'induire une rémission prolongée chez environ 20-30% des patients.
Demerlé, Clémence
core  

Doktorens bord: Hjælp til hvem? [PDF]

Doktorens bord: Hjælp til ...
Rask Pedersen, Mikkel
core  

Modulation of LIGHT-HVEM costimulation prolongs cardiac allograft survival

, 2002
LIGHT (TNFSF14), a tumor necrosis factor superfamily member expressed by activated T cells, binds to herpes virus entry mediator (HVEM) which is constitutively expressed by T cells and costimulates T cell activation in a CD28-independent manner.
Hancock, WW, Gutierrez-Ramos, JC, Busfield, SJ, Wang, L, Ye, Q, Gao, W, Wang, C, Fraser, CC, Qiu, Y, Coyle, AJ   +9 more
core   +1 more source

HVEM signaling in monocytes is mediated by intracellular calcium mobilization

, 2019
Herpes virus entry mediator (HVEM) is a member of the TNF receptor (TNFR) superfamily and is expressed on many immune cells, including T and B cells, NK cells, monocytes, and nentrophils.
Kim, BS, Heo, SK, Yoon, MA, Lee, SC, Ju, SA, Kwon, BS, Suh, PG, Choi, JH   +7 more
core   +1 more source

Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation - Design, Synthesis, and Cellular Studies

, 2020
One of the major current trends in cancer immunotherapy is the blockade of immune checkpoint proteins that negatively regulate the immune response. This has been achieved through antibodies blocking PD-1/PD-L1 and CTLA-4/CD80/CD86 interactions.
Claire Battin, Katarzyna Kuncewicz, Michał Pikuła, Peter Steinberger, Adam Sieradzan, Marta Spodzieja, Agnieszka Karczyńska, Marta Orlikowska, Anna Wardowska, Sylwia Rodziewicz-Motowidło   +9 more
core   +1 more source

Hvem var de danske nazister?

, 2019
Hvem var de danske ...
Christensen, Claus Bundgård
core